


# 글로벌 제약사 파이프라인 분석

## - Eli Lilly -

2022. 09.


국가신약개발사업단

• 질환별 파이프라인



질환분야	개수	비중
Oncology	17	26.5%
Metabolic	16	25%
Neurology	12	19%
Cardiovascular	8	12.5%
Immunology	8	12.5%
Dermatology	2	3%
Renal	1	1.5%
<b>합계</b>	<b>64개</b>	<b>100%</b>

• 물질별 파이프라인



물질	개수	비중
Small molecules	34	53%
Antibody	13	20%
N/A(Not Applicable)	6	9%
Protein	3	5%
Gene Therapy	3	5%
Peptide	3	5%
RNA	2	3%
<b>합계</b>	<b>64개</b>	<b>100%</b>

## • 상세 파이프라인

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
1	Cardiovascular	Phase 3	BI-10773	Jardiance	empagliflozin	Post myocardial infarction	Small molecules	SGLT2	SGLT2 inhibitor	Mono	Boehringer Ingelheim
2	Cardiovascular	Phase 3	LY3298176	Mounjaro	tirzepatide	Heart failure with reduced ejection fraction	Small molecules	GIP, GLP-1	GIP, GLP-1 agonist	Mono	-
3	Cardiovascular	Phase 3	LY3298176	Mounjaro	tirzepatide	Cardiovascular outcomes	Small molecules	GIP, GLP-1	GIP, GLP-1 agonist	Mono	-
4	Cardiovascular	Phase 1	LY-3461767		NRG4 agonist	Heart failure with reduced ejection fraction	N/A	NRG4	NRG4 agonist	Mono	-
5	Cardiovascular	Phase 1	LY-3473329		Lp(a) inhibitor	Cardiovascular disease	Small molecules	Lp(a)	Lp(a) inhibitor	Mono	-
6	Cardiovascular	Phase 1	LY-3540378		Relaxin-LA	Heart failure	Protein	RXFP	RXFP agonist	Mono	-
7	Cardiovascular	Phase 1	LY-3561774		ANGPTL3 siRNA	Cardiovascular disease	RNA	ANGPTL3	ANGPTL3 inhibitor	Mono	Dicerna
8	Cardiovascular	Phase 1	LY-3819469		Lp(a) siRNA	Cardiovascular disease	RNA	Lp(a)	N/A	Mono	-
9	Dermatology	Phase 3			lebrikizumab	Atopic dermatitis	Antibody	IL-13	IL-13 inhibitor	Mono	Genentech
10	Dermatology	Phase 2	LY3041658		CXCR1/2 ligand monoclonal antibody	Hidradenitis suppurativa	Antibody	CXCR1/2	CXCR1/2 antagonist	Mono	-
11	Immunology	Registration	LY3074828		mirikizumab	Ulcerative colitis	Antibody	IL-23	IL-23 inhibitor	Mono	-
12	Immunology	Phase 3	LY3074828		mirikizumab	Crohn's disease	Antibody	IL-23	IL-23 inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
13	Immunology	Phase 2	LY3471851		rezpegaldesle ukin	Systemic lupus erythematosus	Protein	IL-2	IL-2 agonist	Mono	Nektar
14	Immunology	Phase 2			peresolimab	Rheumatoid arthritis	Antibody	PD-1	PD-1 agonist	Mono	-
15	Immunology	Phase 1	LY-3361237		BTLA antibody agonist	Immunology	Antibody	BTLA	BTLA agonist	Mono	-
16	Immunology	Phase 1			CD19 antibody	Immunology	Antibody	CD19	N/A	Mono	-
17	Immunology	Phase 1			CD200R antib ody agonist	Immunology	Antibody	N/A	CD200R antibody agon ist	Mono	-
18	Immunology	Phase 1			RIPK1 inhibitor	Immunology	Small molecules	RIPK1	RIPK1 inhibitor	Mono	-
19	Metabolic	Phase 3	LY3209590		basal insulin-Fc	Diabetes	Protein	INSR	INSR agonist	Mono	-
20	Metabolic	Phase 3	LY3298176	Mounjaro	tirzepatide	Obesity	Small molecules	GIP, GLP-1	GIP, GLP-1 agonist	Mono	-
21	Metabolic	Phase 2	LY3298176	Mounjaro	tirzepatide	Non-alcoholic steatohepatitis (NASH)	Small molecules	GIP, GLP-1	GIP, GLP-1 agonist	Mono	-
22	Metabolic	Phase 2	LY-3437943		GGG Tri-agoni st	Diabetes	N/A	BIP, GCG, GLP-1	BIP, GCG, GLP-1 agonist	Mono	-
23	Metabolic	Phase 2	LY-3437943		GGG Tri-agoni st	Obesity	N/A	BIP, GCG, GLP-1	BIP, GCG, GLP-1 agonist	Mono	-
24	Metabolic	Phase 2	LY-3502970		GLP-1 receptor NPA	Obesity	Small molecules	GLP-1	GLP-1 agonist	Mono	-
25	Metabolic	Phase 2	LY-3502970		GLP-1 receptor NPA	Diabetes	Small molecules	GLP-1	GLP-1 agonist	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
26	Metabolic	Phase 2	PR-001		GBA1 Gene therapy	Gaucher disease type 2	Gene Therapy	N/A	N/A	Mono	-
27	Metabolic	Phase 1	IBI-362		Oxyntomodulin	Diabetes	Peptide	GIP/GLP-1	GIP/GLP-1 agonist	Mono	-
28	Metabolic	Phase 1	LY-3457263		Peptide YY analog agonist	Diabetes	Peptide	Peptide YY	Peptide YY analog agonist	Mono	-
29	Metabolic	Phase 1	LY-3493269		GIP/GLP coag onist peptide	Diabetes	Peptide	GIP/GLP-1	GIP/GLP-1 agonist	Mono	-
30	Metabolic	Phase 1			Amylin agonist long acting	Obesity	N/A	IAPP	IAPP activator	Mono	-
31	Metabolic	Phase 1			GIPR agonist long acting	Diabetes	N/A	GIP receptor	GIP agonist	Mono	-
32	Metabolic	Phase 1			GIPR agonist long acting II	Diabetes	N/A	GIP receptor	GIP agonist	Mono	-
33	Metabolic	Phase 1			KHK inhibitor II	Diabetes	Small molecules	KHK	KHK inhibitor	Mono	-
34	Metabolic	Phase 1			Non-disclosed	Diabetes	Small molecules	N/A	N/A	Mono	-
35	Neurology	Phase 3	LY2062430		solanezumab	Alzheimer's disease	Antibody	Beta amyloid	Beta amyloid inhibitor	Mono	-
36	Neurology	Phase 3	LY3002813		donanemab	Alzheimer's disease	Antibody	Beta amyloid	Beta amyloid inhibitor	Mono	-
37	Neurology	Phase 3	LY3002813		donanemab	Early Alzheimer's disease	Antibody	Beta amyloid	Beta amyloid inhibitor	Mono	-
38	Neurology	Phase 2	LY3372689		O-GlcNAcase Inhibitor	Alzheimer's disease	Small molecules	O-GlcNAcase	O-GlcNAcase Inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
39	Neurology	Phase 2	LY-3451838		PACAP38 antibody	Migraine	Antibody	PACAP38	PACAP38 inhibitor	Mono	-
40	Neurology	Phase 2	LY3526318		TRPA1 antagonist	Pain	Small molecules	TRPA1	TRPA1 antagonist	Mono	-
41	Neurology	Phase 2	LY3556050		SSTR4 agonist	Pain	Small molecules	SSTR4	SSTR4 agonist	Mono	-
42	Neurology	Phase 2	PR-001		GBA1 Gene therapy	Parkinson's	Gene Therapy	N/A	N/A	Mono	-
43	Neurology	Phase 2			GRN Gene therapy	Frontotemporal dementia	Gene Therapy	N/A	N/A	Mono	-
44	Neurology	Phase 2			Mevidalen	Symptomatic lewy body dementia	Small molecules	DRD1	DRD1 agonist	Mono	-
45	Neurology	Phase 1	AK-1780		P2X7 inhibitor	Pain	Small molecules	P2X7	P2X7 inhibitor	Mono	-
46	Neurology	Phase 1	LY-3372993		N3pG4	Alzheimer's disease	Antibody	Amyloid Beta A4 Protein (ABPP)	ABPP inhibitor	Mono	-
47	Oncology	Phase 3	LY2835219	Verzenio	abemaciclib	Castrate resistant prostate cancer	Small molecules	CDK4/6	CDK4/6 inhibitor	Mono	-
48	Oncology	Phase 3	LY2835219	Verzenio	abemaciclib	Myeloid blast crisis sequencing	Small molecules	CDK4/6	CDK4/6 inhibitor	Mono	-
49	Oncology	Phase 3	LY2835219	Verzenio	abemaciclib	Hormone sensitive prostate cancer	Small molecules	CDK4/6	CDK4/6 inhibitor	Mono	-
50	Oncology	Phase 3	LY3484356		imlunestrant	ER+HER2- metastatic breast cancer	Small molecules	ESR1/2	ESR1/2 antagonist	Mono	-
51	Oncology	Phase 3	LY3527723	Retsevmo	selpercatinib	1L NSCLC	Small molecules	RET	RET inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
52	Oncology	Phase 3	LY3527723	Retsevmo	selpercatinib	Adjuvant RET+NSCLC	Small molecules	RET	RET inhibitor	Mono	-
53	Oncology	Phase 3	LY3527723	Retsevmo	selpercatinib	1L medullary thyroid cancer	Small molecules	RET	RET inhibitor	Mono	-
54	Oncology	Phase 3	LY3527727		pirtobrutinib	Relapsed/refractory chronic lymphocytic leukemia	Small molecules	BTK	BTK inhibitor	Combination	-
55	Oncology	Phase 3	LY3527727		pirtobrutinib	Relapsed/refractory chronic lymphocytic leukemia	Small molecules	BTK	BTK inhibitor	Mono	-
56	Oncology	Phase 3	LY3527727		pirtobrutinib	Relapsed/refractory mantle cell lymphoma	Small molecules	BTK	BTK inhibitor	Mono	-
57	Oncology	Phase 3	LY3527727		pirtobrutinib	Relapsed/refractory mantle cell lymphoma (Prior BTK)	Small molecules	BTK	BTK inhibitor	Mono	-
58	Oncology	Phase 3	LY3527727		pirtobrutinib	1L chronic lymphocytic leukemia	Small molecules	BTK	BTK inhibitor	Mono	-
59	Oncology	Phase 2	LY3527727		pirtobrutinib	B-Cell malignancies	Small molecules	BTK	BTK inhibitor	Mono	-
60	Oncology	Phase 1	LOXO-338		BCL2	Cancer	Small molecules	BCL2	BCL2 inhibitor	Mono	Loxo
61	Oncology	Phase 1			IDH1/2 inhibitor	Cancer	Small molecules	IDH1/2	IDH1/2 inhibitor	Mono	-
62	Oncology	Phase 1			KRAS G12C II	Cancer	Small molecules	KRAS	KRAS inhibitor	Mono	-
63	Oncology	Phase 1			RET inhibitor II	Cancer	Small molecules	RET	RET inhibitor	Mono	-
64	Renal	Phase 3	BI-10773	Jardiance	empagliflozin	Chronic kidney disease	Small molecules	SGLT2	SGLT2 inhibitor	Mono	Boehringer Ingelheim